Immunocore Holdings plc Profit Loss Before Tax
Immunocore Holdings plc (IMCR) reported Profit Loss Before Tax of -GBP 13.93 million for the 3-month period ending 2023-06-30, per its 6-K filed 2023-08-10.
Discontinued › Notes
ifrs-full:ProfitLossBeforeTax · last filed 2023-08-10
- Immunocore Holdings plc profit loss before tax for the quarter ending 2023-06-30 was -13.93M GBP.
- Immunocore Holdings plc profit loss before tax for the quarter ending 2022-12-31 was -23.07M GBP.
- Immunocore Holdings plc profit loss before tax for the quarter ending 2022-09-30 was 4.98M GBP.
- Immunocore Holdings plc profit loss before tax for the quarter ending 2022-06-30 was -8.27M GBP.
| Period end | Profit Loss Before Tax 3 month | Profit Loss Before Tax 6 month | Profit Loss Before Tax 9 month | Profit Loss Before Tax 12 month |
|---|---|---|---|---|
| 2023-06-30 | -13.93M GBP 6-K · filed 2023-08-10 | -30.39M GBP 6-K · filed 2023-08-10 | ||
| 2022-12-31 | -23.07M GBP derived: 20-F 12 month − 6-K/A 9 month · filed 2023-03-01 | -18.09M GBP derived: sum of 2 quarters · filed 2023-03-01 | -26.36M GBP derived: sum of 3 quarters · filed 2023-08-10 | -44.15M GBP 20-F · filed 2023-03-01 |
| 2022-09-30 | 4.98M GBP 6-K/A · filed 2022-11-18 | -3.29M GBP derived: sum of 2 quarters · filed 2023-08-10 | -21.07M GBP 6-K/A · filed 2022-11-18 | |
| 2022-06-30 | -8.27M GBP 6-K · filed 2023-08-10 | -26.05M GBP 6-K · filed 2023-08-10 | ||
| 2021-12-31 | -39.17M GBP derived: 20-F 12 month − 6-K/A 9 month · filed 2023-03-01 | -71.43M GBP derived: sum of 2 quarters · filed 2023-03-01 | -140.93M GBP 20-F · filed 2023-03-01 | |
| 2021-09-30 | -32.26M GBP 6-K/A · filed 2022-11-18 | -101.75M GBP 6-K/A · filed 2022-11-18 | ||
| 2020-12-31 | -87.36M GBP 20-F · filed 2023-03-01 | |||
| 2019-12-31 | -126.19M GBP 20-F · filed 2022-03-03 | |||
| 2018-12-31 | -88.18M GBP 20-F · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |